Home Online Features FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Hand-out
Press Releases
Eisai Inc.  
January 26, 2025

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social